FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19 million, ...

The Class Action alleges that, during the Class Period, Defendants shipped excess products to its customers and filed false claims with insurers, including Tricare (the health insurance program for ...